TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells
TC BioPharm (OTC: TCBPY) has secured a significant patent from the European Patent Office for its modified gamma delta T cell therapies targeting microbial, oncological, and viral indications. The patent strengthens the company's intellectual property portfolio in the development of allogeneic cell therapies.
According to CEO Bryan Kobel, this patent advancement is particularly important as it addresses the challenge of off-target recognition in modified cell therapies, potentially enabling broader therapeutic applications while reducing toxicity risks. The company plans to proceed with the patent process in specific European countries in line with its commercial strategy.
TC BioPharm (OTC: TCBPY) ha ottenuto un importante brevetto dall'Ufficio Brevetti Europeo per le sue terapie cellulari gamma delta modificate, mirate a indicazioni microbiche, oncologiche e virali. Il brevetto rafforza il portafoglio di proprietà intellettuale dell'azienda nello sviluppo di terapie cellulari allogeniche.
Secondo il CEO Bryan Kobel, questo progresso brevettuale è particolarmente significativo poiché affronta la sfida del riconoscimento non mirato nelle terapie cellulari modificate, potenzialmente consentendo applicazioni terapeutiche più ampie e riducendo i rischi di tossicità. L'azienda prevede di procedere con il processo di brevetto in specifici paesi europei in linea con la sua strategia commerciale.
TC BioPharm (OTC: TCBPY) ha obtenido una patente significativa de la Oficina Europea de Patentes para sus terapias celulares T gamma delta modificadas dirigidas a indicaciones microbianas, oncológicas y virales. La patente fortalece el portafolio de propiedad intelectual de la empresa en el desarrollo de terapias celulares alogénicas.
Según el CEO Bryan Kobel, este avance en la patente es especialmente importante ya que aborda el desafío del reconocimiento fuera de objetivo en las terapias celulares modificadas, lo que potencialmente permite aplicaciones terapéuticas más amplias mientras se reducen los riesgos de toxicidad. La empresa planea proceder con el proceso de patente en países europeos específicos de acuerdo con su estrategia comercial.
TC BioPharm (OTC: TCBPY)는 유럽 특허청으로부터 미생물, 종양학 및 바이러스적 적응증을 목표로 하는 수정된 감마 델타 T 세포 요법에 대한 중요한 특허를 확보했습니다. 이 특허는 동종 세포 요법 개발에서 회사의 지적 재산 포트폴리오를 강화합니다.
CEO인 브라이언 코벨(Bryan Kobel)에 따르면, 이번 특허 발전은 수정된 세포 요법에서 비표적 인식 문제를 해결하는 데 특히 중요하며, 이는 잠재적으로 더 넓은 치료적 응용을 가능하게 하고 독성 위험을 줄일 수 있습니다. 회사는 상업 전략에 따라 특정 유럽 국가에서 특허 절차를 진행할 계획입니다.
TC BioPharm (OTC: TCBPY) a obtenu un brevet significatif de l'Office Européen des Brevets pour ses thérapies cellulaires T gamma delta modifiées ciblant des indications microbiennes, oncologiques et virales. Ce brevet renforce le portefeuille de propriété intellectuelle de l'entreprise dans le développement de thérapies cellulaires allogéniques.
Selon le PDG Bryan Kobel, cette avancée en matière de brevet est particulièrement importante car elle aborde le défi de la reconnaissance hors cible dans les thérapies cellulaires modifiées, permettant potentiellement des applications thérapeutiques plus larges tout en réduisant les risques de toxicité. L'entreprise prévoit de poursuivre le processus de brevet dans des pays européens spécifiques en accord avec sa stratégie commerciale.
TC BioPharm (OTC: TCBPY) hat ein bedeutendes Patent vom Europäischen Patentamt für seine modifizierten gamma delta T-Zelltherapien erhalten, die auf mikrobiologische, onkologische und virale Indikationen abzielen. Das Patent stärkt das geistige Eigentum des Unternehmens im Bereich der Entwicklung von allogenen Zelltherapien.
Laut CEO Bryan Kobel ist dieser Patentfortschritt besonders wichtig, da er die Herausforderung der Off-Target-Erkennung bei modifizierten Zelltherapien angeht, was potenziell breitere therapeutische Anwendungen ermöglicht und gleichzeitig das Risiko von Toxizität verringert. Das Unternehmen plant, den Patentprozess in bestimmten europäischen Ländern gemäß seiner kommerziellen Strategie fortzusetzen.
- Secured new European patent strengthening intellectual property portfolio
- Technology addresses key limitation in cell therapy (off-target recognition)
- Patent enables expansion into multiple therapeutic areas (microbial, oncological, viral)
- None.
The Company intends to proceed with the patent process in specific European countries, in alignment with the existing commercial strategy.
"The expanding patent portfolio secures our future development of high-value assets," said Bryan Kobel, CEO of TC BioPharm. "The potential for off-target recognition of healthy tissues limits the application of modified cell therapies. By refining the targeting of these modified cells, we can apply high-impact therapies to a broad spectrum of indications while mitigating the toxicity risks associated with modified cell therapies."
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-grant-of-european-patent-for-targeting-of-microbial-oncological-and-viral-indications-using-modified-gamma-delta-t-cells-302424262.html
SOURCE TC BioPharm
FAQ
What is the significance of TCBPY's new European patent for modified gamma delta T cells?
How does TCBPY's patented technology address current limitations in cell therapy?
What are the next steps for TCBPY following the European patent grant?
What therapeutic areas will TCBPY's patented gamma delta T cell technology target?
